25. D’Amato V et al (2015) Mechanisms of lapatinib resistance in HER2-driven breast cancer.
Cancer Treat Rev 41(10):877–883
26. Bachelot T et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain
metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group
phase 2 study. Lancet Oncol 14(1):64–71
27. Long X-H et al (2014) Lapatinib alters the malignant phenotype of osteosarcoma cells via
downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep 31
(1):328–334
28. Chen J-C et al (2014) Suppression of Dicer increases sensitivity to gefitinib in human lung
cancer cells. Ann Surg Oncol 21(4):555–563
29. Mok TS et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl
J Med 361(10):947–957
30. Sim EHA et al (2018) Gefitinib for advanced non-small cell lung cancer. Cochrane Database
Syst Rev 1:CD006847
31. Neal JW (2010) The SATURN trial: the value of maintenance erlotinib in patients with nonsmall-cell lung cancer. Future Oncol 6(12):1827–1832
32. Wang JP et al (2015) Erlotinib is effective in pancreatic cancer with epidermal growth factor
receptor mutations: a randomized, open-label, prospective trial. Oncotarget 6
(20):18162–18173
33. Cappuzzo F (2013) Erlotinib in the first-line treatment of non-small-cell lung cancer AU –
D’Arcangelo, Manolo. Expert Rev Anticancer Ther 13(5):523–533
34. Paz-Ares L et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive
advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung
7 trial. Ann Oncol 28(2):270–277
35. Wu YL et al (2013) LUX-Lung 6: a randomized, open-label, phase III study of afatinib
(A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (PTS) with
EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 31
(15_suppl):8016–8016
36. Morris S et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in
non-Hodgkin’s lymphoma. Science 263(5151):1281–1284
37. Morris SW et al (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in
non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly
related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175
38. Hallberg B, Palmer RH (2016) The role of the ALK receptor in cancer biology. Ann Oncol 27
(suppl_3):iii4–iii15
39. Stute C et al (2004) Myoblast determination in the somatic and visceral mesoderm depends on
Notch signalling as well as on milliways(mili
Alk ) as receptor for Jeb signalling. Development
131(4):743–754
40. Janoueix-Lerosey I et al (2018) The ALK receptor in sympathetic neuron development and
neuroblastoma. Cell Tissue Res 372(2):325–337
41. Yao S et al (2013) Anaplastic lymphoma kinase is required for neurogenesis in the developing
central nervous system of zebrafish. PLoS One 8(5):e63757
42. Yip PY (2015) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3KAkt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res 4
(2):165–176
43. An R et al (2016) CRKL mediates EML4-ALK signaling and is a potential therapeutic target
for ALK-rearranged lung adenocarcinoma. Oncotarget 7(20):29199–29210
44. Umapathy G et al (2014) The kinase ALK stimulates the kinase ERK5 to promote the
expression of the oncogene MYCN in neuroblastoma. Sci Signal 7(349):ra102
45. Hallberg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in
human cancer biology. Nat Rev Cancer 13:685
46. Soda M et al (2007) Identification of the transforming EML4–ALK fusion gene in non-smallcell lung cancer. Nature 448:561
146
A. Moschopoulou et al.
Cancer Treat Rev 41(10):877–883
26. Bachelot T et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain
metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group
phase 2 study. Lancet Oncol 14(1):64–71
27. Long X-H et al (2014) Lapatinib alters the malignant phenotype of osteosarcoma cells via
downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep 31
(1):328–334
28. Chen J-C et al (2014) Suppression of Dicer increases sensitivity to gefitinib in human lung
cancer cells. Ann Surg Oncol 21(4):555–563
29. Mok TS et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl
J Med 361(10):947–957
30. Sim EHA et al (2018) Gefitinib for advanced non-small cell lung cancer. Cochrane Database
Syst Rev 1:CD006847
31. Neal JW (2010) The SATURN trial: the value of maintenance erlotinib in patients with nonsmall-cell lung cancer. Future Oncol 6(12):1827–1832
32. Wang JP et al (2015) Erlotinib is effective in pancreatic cancer with epidermal growth factor
receptor mutations: a randomized, open-label, prospective trial. Oncotarget 6
(20):18162–18173
33. Cappuzzo F (2013) Erlotinib in the first-line treatment of non-small-cell lung cancer AU –
D’Arcangelo, Manolo. Expert Rev Anticancer Ther 13(5):523–533
34. Paz-Ares L et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive
advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung
7 trial. Ann Oncol 28(2):270–277
35. Wu YL et al (2013) LUX-Lung 6: a randomized, open-label, phase III study of afatinib
(A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (PTS) with
EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 31
(15_suppl):8016–8016
36. Morris S et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in
non-Hodgkin’s lymphoma. Science 263(5151):1281–1284
37. Morris SW et al (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in
non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly
related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175
38. Hallberg B, Palmer RH (2016) The role of the ALK receptor in cancer biology. Ann Oncol 27
(suppl_3):iii4–iii15
39. Stute C et al (2004) Myoblast determination in the somatic and visceral mesoderm depends on
Notch signalling as well as on milliways(mili
Alk ) as receptor for Jeb signalling. Development
131(4):743–754
40. Janoueix-Lerosey I et al (2018) The ALK receptor in sympathetic neuron development and
neuroblastoma. Cell Tissue Res 372(2):325–337
41. Yao S et al (2013) Anaplastic lymphoma kinase is required for neurogenesis in the developing
central nervous system of zebrafish. PLoS One 8(5):e63757
42. Yip PY (2015) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3KAkt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res 4
(2):165–176
43. An R et al (2016) CRKL mediates EML4-ALK signaling and is a potential therapeutic target
for ALK-rearranged lung adenocarcinoma. Oncotarget 7(20):29199–29210
44. Umapathy G et al (2014) The kinase ALK stimulates the kinase ERK5 to promote the
expression of the oncogene MYCN in neuroblastoma. Sci Signal 7(349):ra102
45. Hallberg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in
human cancer biology. Nat Rev Cancer 13:685
46. Soda M et al (2007) Identification of the transforming EML4–ALK fusion gene in non-smallcell lung cancer. Nature 448:561
146
A. Moschopoulou et al.